carmustine has been researched along with Pulmonary Embolism in 2 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
Pulmonary Embolism: Blocking of the PULMONARY ARTERY or one of its branches by an EMBOLUS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The combination of dacarbazine (DTIC, 220 mg/m2) and cisplatin (DDP, 25 mg/m2) IV daily for 3 days every 3 weeks, carmustine (BCNU, 150 mg/m2) IV every 6 weeks, and tamoxifen (TAM, 10 mg orally twice daily) produced a 50% objective response rate in patients with metastatic melanoma." | 7.67 | The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma. ( Bellet, RE; Berd, D; Mastrangelo, MJ; McClay, EF; Sprandio, JD, 1989) |
| "The combination of dacarbazine (DTIC, 220 mg/m2) and cisplatin (DDP, 25 mg/m2) IV daily for 3 days every 3 weeks, carmustine (BCNU, 150 mg/m2) IV every 6 weeks, and tamoxifen (TAM, 10 mg orally twice daily) produced a 50% objective response rate in patients with metastatic melanoma." | 3.67 | The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma. ( Bellet, RE; Berd, D; Mastrangelo, MJ; McClay, EF; Sprandio, JD, 1989) |
| "Twenty-three patients with metastatic melanoma were treated with combination therapy consisting of dacarbazine (220 mg/m2) and cisplatin (25 mg/m2) iv daily for 3 days every 3 weeks, carmustine (150 mg/m2) iv every 6 weeks, and tamoxifen (10 mg) orally twice daily." | 3.67 | Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma. ( Bellet, RE; Berd, D; Mastrangelo, MJ; McClay, EF, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| McClay, EF | 2 |
| Mastrangelo, MJ | 2 |
| Sprandio, JD | 1 |
| Bellet, RE | 2 |
| Berd, D | 2 |
2 other studies available for carmustine and Pulmonary Embolism
| Article | Year |
|---|---|
The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Hematolo | 1989 |
Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Fem | 1987 |